Premium
Hepatitis B and hepatitis C co‐infection in patients with HIV
Author(s) -
Herrero Martínez E.
Publication year - 2001
Publication title -
reviews in medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.06
H-Index - 90
eISSN - 1099-1654
pISSN - 1052-9276
DOI - 10.1002/rmv.323
Subject(s) - medicine , hepatitis c , immunology , liver disease , hepatitis b , life expectancy , hepatitis c virus , chronic infection , population , disease , hepatitis b virus , epidemiology , coinfection , hepatitis , virology , virus , immune system , environmental health
An Erratum has been published for this article in Reviews in Medical Virology 11 (5) 2001, 343 HAART has increased the life expectancy of patients with HIV. However, as their life expectancy increases, it becomes increasingly important to focus on the management of concurrent illnesses such as chronic HBV and HCV infections which have the potential to increase mid to long term morbidity and mortality. Shared epidemiological risks have resulted in the HIV infected population having a higher incidence of both HBV and HCV than those uninfected with HIV. Co‐infection with HIV modifies the natural history of HBV infection, increasing the rate of viral replication, risk of carriage and chronic hepatitis but without increasing liver necroinflammatory processes. In chronic HCV infection, the presence of HIV enhances the risk of severe liver disease. There is no evidence as yet that HBV directly impacts on HIV disease progression but HCV infection increases the risk of death or an AIDS defining illness and impairs CD4+ T cell recovery during antiretroviral therapy. Treatment of either hepatitis virus is complex because of pharmacokinetic interactions with components of HAART regimens. Copyright © 2001 John Wiley & Sons, Ltd.